European Journal of Radiology
Volume 73, Issue 2 , Pages 294-299 , February 2010

Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer

  • Albert Dirisamer

      Affiliations

    • Department of Nuclear Medicine, St. Vincent's Hospital, Seilerstaette 4, 4010 Linz, Austria
    • Department of Radiology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author at: Department of Radiology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria. Tel.: +43 1 40400 4893; fax: +43 1 40400 4894.
    • ,
  • Benjamin S. Halpern

      Affiliations

    • Department of Radiology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria
    • ,
  • Daniel Flöry

      Affiliations

    • Department of Radiology, General Hospital of Linz, Austria
    • ,
  • Florian Wolf

      Affiliations

    • Department of Radiology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria
    • ,
  • Mohsen Beheshti

      Affiliations

    • Department of Nuclear Medicine, St. Vincent's Hospital, Seilerstaette 4, 4010 Linz, Austria
    • ,
  • Marius E. Mayerhoefer

      Affiliations

    • Department of Radiology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090 Vienna, Austria
    • ,
  • Werner Langsteger

      Affiliations

    • Department of Nuclear Medicine, St. Vincent's Hospital, Seilerstaette 4, 4010 Linz, Austria

Received 16 October 2008 ,Revised 23 October 2008 ,Accepted 27 October 2008.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55(January–February(1)):10–30. Erratum in: CA Cancer J Clin 2005;55(July–August(4)):259.
  2. Sugg SL, Ferguson DJ, Posner MC, Heimann R. Should internal mammary nodes be sampled in the sentinel lymph node era?. Ann Surg Oncol. 2000;7:188–192
  3. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?. Cancer. 1994;73:664–667
  4. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43:325–329
  5. Cook GJ, Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med. 1999 Jan;29(1):69–79
  6. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004;233:433–440
  7. Dirisamer A, Schima W, Heinisch M, et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol. 2008;(January 11):
  8. Kitajima K, Murakami K, Yamasaki E, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. Eur J Nucl Med Mol Imaging. 2008;(August 6):
  9. An YS, Sun JS, Park KJ, et al. Diagnostic performance of (18)F-FDG PET/CT for lymph node staging in patients with operable non-small-cell lung cancer and inflammatory lung disease. Lung. 2008;(August 1):
  10. Tessonnier L, Sebag F, Palazzo FF, et al. Does (18)F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?. Eur J Nucl Med Mol Imaging. 2008;(June 20):
  11. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol. 1985;144:261–265
  12. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Ohkawa M. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–638
  13. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819–1824
  14. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr;247(1):189–196
  15. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007;34(October(10)):1583–1593
  16. Karantanis D, O’Neill BP, Subramaniam RM, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med. 2007 Apr;32(4):271–274
  17. Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28(May(5)):300–306
  18. Poettgen C, Theegarten D, Eberhardt W, et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology. 2007;73(5–6):316–323
  19. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11(April(4)):472–478
  20. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging. 2008;33(January–February(1)):112–118
  21. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging -- do we need contrast-enhanced CT?. Radiology. 2004;232(September(3)):823–829
  22. Veit-Haibach P, Antoch G, Beyer T, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007;80(July(955)):508–515
  23. Fueger BJ, Weber WA, Quon A, et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005;7(Septmber–October(5)):369–376
  24. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–4368
  25. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. J Am Med Assoc. 2003;290:3199–3206
  26. Kamel E, Wyss M, Fehr M, Schulthess von G, Goerres W. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129:147–153
  27. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun. 2002;23:857–864
  28. Gallowitsch H, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38:250–256
  29. Moon DH, Maddahi J, Silverman DHS, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431–435
  30. Cook GJ, Houston S, Rubens R, Maisey MN. Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998 Oct;16(10):3375–3379
  31. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743–750
  32. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 1998;39:4–8
  33. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med. 1996;23:1588–1593
  34. Greco M, Crippa F, Agresti R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst. 2001;93:630–635
  35. Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol. 2008;65(January):47–58

PII: S0720-048X(08)00593-7

doi: 10.1016/j.ejrad.2008.10.031

European Journal of Radiology
Volume 73, Issue 2 , Pages 294-299 , February 2010

Article Tools

* Image Usage & Resolution